Skip to main content
SpringerLink
Log in

Recent reflections on tumor markers

  • Published:
World Journal of Urology Aims and scope Submit manuscript

Summary

The necessity for monitoring serum levels of alphafetoprotein (AFP) and human chorionic gonadotropin (hCG) in patients with testicular cancer is widely known, but a few questions remain unanswered. Cross-reactivity of commercial hCG assays with luteinizing hormone remains a problem; and as patients apparently cured of testicular cancer age, they become subject to other diseases that can elevated AFP or hCG levels, creating confusion. There still are no adequate studies of the role of markers in staging, a problem that has become acute with the introduction of expectant treatment for metastases in clinical stage A disease. Calculation of the metabolic half-life of markers can be helpful in staging postoperatively, but calculations of the actual half-life of markers during induction chemotherapy is less useful than had once been hoped. Attempts to capitalize on the molecular heterogeneity of AFP have had little success, although newer analytic methods may change this; but ultrasensitive assays for urinary hCG are beginning to show promise. Studies of radioimmunodetection with anti-marker antibodies have been both encouraging and frustrating; the newly available monoclonal anti-marker antibodies may improve the results and also offer a possible means of improving chemotherapy. Placental alkaline phosphatase continues to look like a useful marker for seminoma, and lactic dehydrogenase is often helpful in all types of testicular cancer, especially in high-stage disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Begent RHJ, Searle F, Stanway G, et al (1980) Radioimmunolocalisation of tumours by external scintigraphy after administration of 131I antibody to human chorionic gonadotropin. J R Soc Med 73:624–627

    Google Scholar 

  2. Bosl GJ, Geller NL, Cirrincione C, et al (1983) Serum markers in patients with metastatic germ cell tumors of the testis. Am J Med 75:29–35

    Google Scholar 

  3. Bosl GJ, Geller NL, Cirrincione C, et al (1983) Interrelationships of histopathology and other clinical variables in patients with germ cell tumors of the testes. Cancer 51:2121–2125

    Google Scholar 

  4. Bosl GJ, Geller NL, Cirrincione C, et al (1983) Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43:3403–3407

    Google Scholar 

  5. Bosl GJ, Lange PH, Nochomovitz LE, et al (1981) Tumor markers in advanced nonseminomatous testicular cancer. Cancer 47:572–576

    Google Scholar 

  6. Braunstein GD, Vaitukaitis JL, Carbone PP, Ross GT (1973) Ectopic production of human chorionic gonadotropin by neoplasms. Ann Intern Med 78:39–43

    Google Scholar 

  7. Breborowicz J, Mackiewicz A (1981) Application of lectin affinity electrophoresis for studies of microheterogeneity of human alphafetoprotein. In: Boghansen TC (ed) Lectins — Biology, biochemistry, clinical biochemistry, vol 1. Walter de Gruyter, Amsterdam, pp 271–292

    Google Scholar 

  8. Brenner J, Vugrin D, Whitmore WF (1982) Cytoreductive surgery for advanced nonseminomatous germ cell tumors of testis. Urology 19:571–575

    Google Scholar 

  9. Damjanov I, Fox N, Knowles BB, Solter D, Lange PH, Fraley EE (1982) Immunohistochemical localization of murine stage-specific embryonic antigens in human testicular germ cell tumors. Am J Pathol 111:156–165

    Google Scholar 

  10. Debruijn HWA, Suurmeijer ASH, Sleijfer DT, et al (1982) Evaluation of pregnancy-specific beta-1-glycoprotein in patients with non-seminomatous testicular germ cell tumors. Eur J Cancer Clin Oncol 18:911–916

    Google Scholar 

  11. Donohue JP, Einhorn LH, Williams SD (1980) Cytoreductive surgery for metastatic testis cancer: considerations of timing and extent. J Urol 123:876–880

    Google Scholar 

  12. Fowler JE Jr, Platoff GE, Kubrock CA, Stutzman RE (1982) Commercial radioimmunoassay for beta subunit of human chorionic gonadotropin: falsely positive determinations due to elevated serum luteinizing hormone. Cancer 49:136–139

    Google Scholar 

  13. Fukutaini K, Libby JM, Panko WB, Scardino PT (1983) Human chorionic gonadotropin detected in urinary concentrates from patients with malignant tumors of the testis, prostate, bladder, ureter and kidney. J Urol 129:74–77

    Google Scholar 

  14. Halsall AK, Fairweather DS, Bradwell AR, et al (1981) Localisation of malignant germ-cell tumours by external scanning after injection of radiolabelled alpha-fetoprotein. Br Med J 283:942–945

    Google Scholar 

  15. Jacobsen GK (1983) Alphafetoprotein and human chorionic gonadotropin in testicular germ cell tumours: a comparison of histological and serological occurrence of tumour markers. Acta Pathol Microbiol Scand [A] 91:183–190

    Google Scholar 

  16. Javadpour N (1980) The role of biologic tumor markers in testicular cancer. Cancer 45:1755–1761

    Google Scholar 

  17. Javadpour N (1983) Multiple biochemical tumor markers in seminoma. Cancer 52:887–889

    Google Scholar 

  18. Javadpour N, Chen HC (1981) Improved human chorionic gonadotropin detection with carboxy-terminal radioimmunoassay of the beta subunit on concentrated 24-hour urine in patients with testicular cancer. J Urol 126:176–178

    Google Scholar 

  19. Javadpour N, Kim EE, DeLand FH, Salyer JR, Goldenberg DM (1981) The role of radioimmunodetection in the management of testicular cancer. JAMA 246:45–49

    Google Scholar 

  20. Jeppsson A, Wahren B, Stigbrand T, Edsmyr F, Andersson L (1983) A clinical evaluation of serum placental alkaline phosphatase in seminoma patients. Br J Med 55:73–78

    Google Scholar 

  21. Kardon FM, Krikorian JG, Lopez JA, de Vere White R (1982) Errors in measurement in reporting of serum markers in patients with germ cell tumors. Urology 20:476–478

    Google Scholar 

  22. Ketchum C, MacLaren N, Jensen J, Phillips I, Weinen R, Kappy M (1982) False increases of β-subunit choriogonadotropin in commercial kit results because of cross reactivity with lutropin. Clin Chem 28:1998–1999

    Google Scholar 

  23. Lange PH (1982) Testicular cancer markers. In: Sell S, Wahren B (eds) Human cancer markers. Humana Press, Clifton NJ, pp 259–273

    Google Scholar 

  24. Lange PH, Raghavan D (1983) Clinical application of tumor markers in testicular cancer. In: Donohue JP (ed) Testis tumors. Williams & Wilkins, Baltimore, pp 111–130

    Google Scholar 

  25. Lange PH, McIntire KR, Waldmann TA (1980) Tumor markers in testicular tumor: current status and future prospects. In: Einhorn LE (ed) Testicular tumors: management and treatment. Masson, New York, pp 69–81

    Google Scholar 

  26. Lange PH, Bremner RD, Horne CHW, Vessella RL, Fraley EE (1982) Is SP-1 a marker for testicular cancer? Urology 15:251–255

    Google Scholar 

  27. Lange PH, Hekmat K, Bosl G, Kennedy BJ, Fraley EE (1980) Accelerated growth of testicular cancer after cytoreductive surgery. Cancer 45:1498–1506

    Google Scholar 

  28. Lange PH, Millan JL, Stigbrand T, Vessella RL, Ruoslahti E, Fishman WH (1982) Placental alkaline phosphatase as a tumor marker for seminoma. Cancer Res 42:3244–3247

    Google Scholar 

  29. Lange PH, Nochomovitz LE, Rosai J, et al (1980) Serum alpha-fetoprotein and human chorionic gonadotropin in patients with seminoma. J Urol 124:472–478

    Google Scholar 

  30. Lange PH, Vogelzang NJ, Anderson RW, Fraley EE, Allen DW (1982) The timing of cytoreductive surgery in men with germ cell tumors (abstract C-267). Proc Am Soc Clin Oncol Am Assoc Cancer Res 18:69

    Google Scholar 

  31. Lange PH, Vogelzang NJ, Fraley EE, Kennedy BJ, DeLand FH, Goldenberg DM (1982) Radioimmunodetection in nonseminomatous germ cell tumors. Presented at the Annual Meeting, American Urological Association, Kansas City

  32. Lange PH, Vogelzang NJ, Goldman A, Kennedy BJ, Fraley EE (1982) Marker half-life analysis as a prognostic tool in testicular cancer. J Urol 128:708–711

    Google Scholar 

  33. Lippert MC, Javadpour N (1981) Lactic dehydrogenase in the monitoring and prognosis of testicular cancer. Cancer 48:2274–2278

    Google Scholar 

  34. Mackiewicz A, Breborowicz J (1981) 3-dimensional affinity electrophoresis of human alphafetoprotein. In: Boghansen TC (ed) Lectins — Biology, biochemistry, clinical biochemistry, vol 1. Walter de Gruyter, Amsterdam, pp 471–292

    Google Scholar 

  35. Narayana AS, Loening S, Weimar G, Culp DA (1979) Serum markers in testicular tumors. J Urol 121:51–53

    Google Scholar 

  36. Newlands ES, Rustin GJS, Begent RH, Parker D, Bagshawe KV (1981) Further advances in the management of malignant teratomas of the testes and other sites. Lancet I: 948–951

    Google Scholar 

  37. Paiva J, Damjanov I, Lange PH, Harris H (1983) Immunohistochemical localization of placental-like alkaline phosphatase in the testes and germ cell tumors using monoclonal antibodies. Am J Pathol 111:156–165

    Google Scholar 

  38. Peckham MJ, Husband JE, Barrett A, Hendry WF (1982) Orchiectomy alone in Stage I non-seminomatous germ-cell tumours. Lancet II: 678–680

    Google Scholar 

  39. Rowland RG, Weisman D, Williams SD, Einhorn LH, Klatte E, Donohue JP (1982) Accuracy of preoperative staging in stage A and B nonseminomatous germ cell testicular tumors. J Urol 127:718–720

    Google Scholar 

  40. Ruoslahti E, Engvall E, Pekkala A, Sepällä M (1978) Developmental changes in carbohydrate moiety of human alpha-fetoprotein. Int J Cancer 22:518–520

    Google Scholar 

  41. Scardino PT, Skinner DG (1979) Germ cell tumors of the testis: improved results in a prospective study using combined modality therapy and biochemical tumor markers. Surgery 86:86–93

    Google Scholar 

  42. Scardino PT, Cox HD, Waldmann TA, McIntire KR, Mittemeyer B, Javadpour N (1977) The value of serum tumor markers in the staging and prognosis of germ cell tumors of the testes. J Urol 118:994–999

    Google Scholar 

  43. Smith CJ, Kelleher PC (1980) Alpha-fetoprotein molecular homogeneity: physiologic correlations with normal growth, carcinogenesis and tumor growth. Biochim Biophys Acta 605:1–25

    Google Scholar 

  44. Solter D, Ballou B, Reilan J, Levine G, Hakala TR, Knowles BB (1982) Radioimmunodetection of tumors using monoclonal antibodies. Prog Cancer Res Ther 21:241–244

    Google Scholar 

  45. Suurmeijer AJH, De Bruijn HWA, Oosterhuis JW, Slayfer DT, Schraffordt Koops H, Fleuren GJ (1982) Non-seminomatous germ cell tumors of the testis: immunohistochemical localization and serum levels of human chorionic gonadotropin (HCG) and pregnancy-specific beta-glycoprotein (SP-1) — value of SP-1 as a tumor marker. Oncodev Biol Med 3:409–412

    Google Scholar 

  46. Terebelo H, Taylor H, Blom J, Stutz H (1983) Late relapse of testicular cancer (Abstract C-526). Proc Am Soc Clin Oncol Am Assoc Cancer Res 19

  47. Tonik SE, Ortmeyer AE, Shindelman JE, Sussman HH (1983) Elevation of serum placental alkaline phosphatase levels in cigarette smokers. Int J Cancer 31:51–53

    Google Scholar 

  48. Vaitukaitis JL (1979) Human chorionic gonadotropin: a hormone secreted for many reasons. N Engl J Med 301:324–326

    Google Scholar 

  49. Vogelzang NJ, Lange PH, Goldman A, Vessella RH, Fraley EE, Kennedy BJ (1982) Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res 42:4855–4861

    Google Scholar 

  50. Vugrin D, Whitmore WF Jr, Nisselbaum J, Watson RC (1982) Correlation of serum tumor markers and lymphangiography with degree of nodal involvement in surgical stage II testis cancer. J Urol 127:638–684

    Google Scholar 

  51. Wehmann RE, Harman SM, Birken S, Canfield RE, Nisula BC (1981) Convenient radioimmunoassay for urinary human choriogonadotropin without interference by urinary human lutotropin. Clin Chem 27:1997–2001

    Google Scholar 

  52. Willemse PHB, Sleyfer H, Fer DTh, et al (1981) Tumor markers in patients with nonseminomatous germ cell tumors of the testes. Oncodev Biol Med 2:117–128

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urologic Surgery, University of Minnesota Health Sciences, Mayo Memorial Building, Box 394, 55455-0321, Minneapolis, MN, USA

    A. Ami Sidi, Rei-Kwen Chiou & Paul H. Lange

  2. Section of Urology, Veterans Administration Medical Center, Minneapolis, Minnesota, USA

    A. Ami Sidi, Rei-Kwen Chiou & Paul H. Lange

Authors
  1. A. Ami Sidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rei-Kwen Chiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul H. Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sidi, A.A., Chiou, RK. & Lange, P.H. Recent reflections on tumor markers. World J Urol 2, 18–25 (1984). https://doi.org/10.1007/BF00326928

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00326928

Keywords

Search

Navigation